Novavax Aims for Billions Covid Vaccine Doses Could Be Available by End of 2021

fiercepharma | August 12, 2020

Some of the world’s largest biopharma companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives say. On a conference call Monday, chief medical officer Filip Dubovsky said the Gaithersburg, MD-based biotech expects to be able to make "well over a couple billion units" each year, starting in 2021. That would easily outpace U.S. demand, which Dubovsky estimated will come in at 500 million to 600 million doses annually.

Spotlight

Global pharma industry is booming – the market for temperature management services is estimated at US$8.36 billion in 2014 and is projected to rise to US$10.28 billion by 2018.

Spotlight

Global pharma industry is booming – the market for temperature management services is estimated at US$8.36 billion in 2014 and is projected to rise to US$10.28 billion by 2018.

Related News

PHARMACY MARKET

Mallax acquires Sana Pharma Medical, Establishing a New Nordic Pharmaceutical Platform

Mallax | July 05, 2021

Mallax Pharmaceuticals AB has acquired Sana Pharma Medical AS, forming a new Nordic pharmaceutical platform. SPM, founded in Norway in 2014, is a rapidly growing OTC company with complete pharmaceutical infrastructure and Nordic distribution coverage. With the well-established brands such as Lunixen and Sedix and additional products based on the chemical melatonin, the Company has a leading position in the fast-growing sleep and anxiety sector. SPM is a well-resourced platform with about 15 FTEs that provides extensive in-house pharmaceutical expertise and experience to serve as an appealing basis for Mallax. Furthermore, the Company has a sizable and steadily growing pipeline of new products that will be released in the future years. Mallax was founded in 2020 by Impilo, a Nordic healthcare-focused investment firm, and Anders Larnholt, a seasoned pharma, and healthcare executive, with the long-term goal of creating a large and diverse platform with established pharmaceuticals and OTC products for customers and patients across Europe. Dr. Peter Sjöstrand, the former deputy CEO and CFO of Astra and the former Chairman of the Boards of Gambro and Meda, is named Chairman of the Board of Mallax as part of the transaction. About Mallax Mallax was founded in 2020 by Impilo and Anders Larnholt with the ambition of building a leading pharma company and investing significant capital and resources behind the right acquisition opportunities across Europe, with a wide size range for any individual deal ranging from EUR 10 million to EUR 300 million. Mallax's strategy is based on three pillars: sustainability, medical need, and profitable growth. Mallax currently has operations in all Nordic markets due to the acquisition of Sana Pharma Medical. About Impilo Impilo is a Nordic investment firm that makes long-term investments in healthcare companies involved in pharmaceuticals, medical technology, healthcare services, and other health-related sectors. Impilo seeks to enhance the value of its assets via long-term active ownership and generate consistent returns for its stakeholders. Impilo has a well-diversified investment portfolio and has raised over SEK 9 billion in capital from leading Nordic and international investors since its inception in 2017.

Read More

RESEARCH

Exscientia and Bristol Myers Squibb Enter Into a Multi-Target, AI-Driven Drug Discovery Partnership

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immunology. The agreement is worth up to $1.2 billion including up to $50 million in upfront funding, and up to $125 million in near-to-mid-term future milestones, and other clinical, regulatory, and commercial payments. Exscientia will also receive tiered royalty based on the net sales of any marketed drug products as a result of the partnership. This extended collaboration builds on Exscientia's existing partnership with Bristol Myers Squibb, which began in 2019 with Celgene before Bristol Myers Squibb purchased Celgene. Exscientia will be in charge of the AI design and experimental work needed to identify drug candidates for Bristol Myers Squibb as part of this partnership. Exscientia's AI-driven drug discovery platform will be used to create molecules and will deliver optimized compounds that meet complex design goals quickly and more efficiently than traditional drug discovery. Exscientia's drug discovery platform has a proven track record and has been the one to advance AI-designed small molecule drug candidates into clinical studies. Exscientia has previously partnered with large pharmaceutical firms such as Bayer, Sanofi, and Dainippon Sumitomo, as well as several new biotech companies and the Gates Foundation, highlighting the company's reputation as the go-to partner for high-value AI-driven drug discovery. More than a dozen partnered or wholly-owned drugs are currently in development in the company. Exscientia recently raised $525 million in a Series D investment led by Softbank to expand its technology capability and proprietary drug pipeline. About Exscientia Exscientia's AI-driven, end-to-end drug discovery platform is designed to revolutionize the process of developing new drugs by creating therapeutics for areas of high unmet medical need that could benefit patients in much less time than industry standards. Exscientia is the first clinical-stage organization to bring AI-designed small molecules to the clinic, demonstrating AI's ability to transform the pharmaceutical industry. At the molecular scale, drug design is precision engineering. Exscientia has built dedicated AI systems that effectively learn from a wide range of data and continuously re-apply enhanced information through design iterations to transform the industry. Candidate molecules satisfying complex therapeutic criteria are discovered with groundbreaking efficiency by Exscientia's AI systems, which learn faster and more efficiently than human-led efforts.

Read More

RESEARCH

Orsini Specialty Pharmacy Expands Collaborates with Alnylam® Pharmaceuticals as a Limited Distribution Partner for Oxlumo™

Orsini | December 04, 2020

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effect that normally is dispensed with by the kidneys and discharged in the pee. The overabundance creation of oxalate brings about the affidavit of calcium oxalate gems in the kidneys and urinary plot and can prompt the development of agonizing and repetitive kidney stones, nephrocalcinosis, movement to kidney disappointment, and foundational organ brokenness. It is assessed that PH1 influences one to three people for each million in the United States and Europe. "We are satisfied to grow our organization with Alnylam Pharmaceuticals and add OXLUMO to the treatments we accommodate the treatment of super uncommon hereditary conditions," said Mike Fieri, Orsini Chief Executive Officer. "Our devoted OXLUMO Care Team is focused on offering caring help and individualized administrations to help individuals with PH1 and their families all through their excursion and assist them with exploring through the complexities of our medical services framework."

Read More